Exploring trade-offs between target coverage, healthy tissue sparing, and the placement of catheters in HDR brachytherapy for prostate cancer using a novel multi-objective model-based mixed-integer evolutionary algorithm by Sadowski, K.L. (Krzysztof) et al.
Exploring Trade-Os between Target Coverage, Healthy Tissue
Sparing, and the Placement of Catheters in HDR Brachytherapy
for Prostate Cancer using a Novel Multi-Objective Model-Based
Mixed-Integer Evolutionary Algorithm
Krzysztof L. Sadowski
Utrecht University
Utrecht, e Netherlands
k.l.sadowski@uu.nl
Marjolein C. van der Meer
Academic Medical Center
Amsterdam, e Netherlands
marjolein.vandermeer@amc.uva.nl
Ngoc Hoang Luong
Centrum Wiskunde & Informatica
Amsterdam, e Netherlands
n.h.luong@cwi.nl
Tanja Alderliesten
Academic Medical Center
Amsterdam, e Netherlands
t.alderliesten@amc.uva.nl
Dirk ierens
Utrecht University
Utrecht, e Netherlands
d.thierens@uu.nl
Rob van der Laarse
Academic Medical Center
Amsterdam, e Netherlands
rob.vanderlaarse@gmail.com
Yury Niatsetski
Elekta
Veenendaal, e Netherlands
yury.niatsetski@elekta.com
Arjan Bel
Academic Medical Center
Amsterdam, e Netherlands
a.bel@amc.uva.nl
Peter A.N. Bosman
Centrum Wiskunde & Informatica
Amsterdam, e Netherlands
peter.bosman@cwi.nl
ABSTRACT
Brachytherapy is a form of radiotherapy whereby a radiation source
is guided near tumors, using devices such as catheter implants. In
the present clinical workow, catheters are rst placed inside or
close to the tumor based on clinical expertise. Subsequently, so-
ware is used to design a plan for the delivery of radiation. Treat-
ment planning is essentially a multi-objective optimization problem,
where conicting objectives represent radiation delivered to tumor
cells and healthy cells. However, current clinical soware collapses
this information into a single-objective, constrained optimization
problem. Moreover, catheter positioning is typically not included.
As a consequence, it is hard to obtain insight into the true nature of
the trade-os between key planning objectives and the placement
of catheters. Such insights are however crucial in understanding
how beer treatment plans may be constructed. To obtain such
insights, we interface with real-world clinical soware and derive
potential catheter positions for real-world patients. Selecting and
conguring catheters requires mixed-integer optimization. For
this reason, we extend the recently-proposed Genetic Algorithm
for Model-Based mixed-Integer opTimization (GAMBIT) to tackle
multi-objective optimization problems. Our results indicate that
clinically acceptable plans of high quality may be achievable with
less catheters than typically used in current clinical practice.
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1 INTRODUCTION
Prostate cancer is the most common type of cancer among men in
the Netherlands, a diagnosis that over 10, 000 men are confronted
with each year, and leading to about 2, 500 deaths per year [11].
Radiotherapy is a commonly applied cancer treatment in which
ionizing radiation is used to target tumor cells. An important form
of radiotherapy for prostate cancer is brachytherapy (BT), where
the tumor is irradiated from inside the body by guiding a radiation
source close to or inside the tumor. In this paper, we focus on the
case whereby catheters are placed in the prostate, for the radiation
source to be moved through. Each catheter contains a number of
dierent positions, called dwell positions, where the source can
dwell for prescribed amounts of time, called dwell times. If the
source dwells at a given dwell position, that position is called active;
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otherwise, it is called inactive. By varying the dwell times, dierent
treatment plans are possible.
In determining a treatment plan, there are multiple aspects of
importance. Firstly, as many tumor cells as possible should ob-
tain a suciently high dose in order to maximize the probability
of damaging or killing cancer cells. Secondly, the dose to nearby
organs cannot be too high, to minimize the probability of compli-
cations. Most current clinical soware for determining a treatment
plan is based on single-objective optimization and manual tun-
ing. However, because of the conicting nature of these objectives,
multi-objective optimization would be a more natural approach
since trade-os can be shown between the dierent objectives of
interest, providing insight into how much may be gained in one ob-
jective at what cost to another. is way, a well-informed decision
may be taken on what is the best treatment plan for the patient at
hand.
Taking also the placement and number of catheters into account
in the multi-objective optimization perspective is a natural t, be-
cause the exact location of catheters governs much of what may
be achieved in terms of plan quality. Moreover, to minimize the
possibility of complications, one should use as few catheters as
possible [6, 8, 14]. Currently, the placement of catheters is done
mostly based on medical expertise. At the hospital involved in this
study there are typically 16 − 18 catheters used. Many placements
are possible and for each placement many treatment plans are pos-
sible, comprising a vast search space. Even though expertise and
literature exists on how to place catheters, there is lile information
on the real-world trade-os of catheter placements. Our goal is to
take a rst step in this direction, obtaining such insights, learning
about the complexity of the multi-objective optimization problem,
and start to work toward algorithms that may really be used for
patient-specic optimization in clinical practice. e novelty in our
approach is bringing together several aspects that were not con-
sidered altogether before. Multi-objective approaches to treatment
planning have been proposed, including catheter placement via the
weighted-sum method in combination with single-objective opti-
mization, but did not optimize directly on the evaluation criteria of
a clinical evaluation protocol [9]. Related work that does optimize
on these criteria exists, but is single-objective and does not consider
catheter placement [5]. In contrast, we consider the use of real-
world clinical soware and patients combined with multi-objective
optimization directly on criteria as considered in clinical evaluation
protocols.
From an algorithmic perspective, Evolutionary Algorithms (EAs)
are among the state-of-the-art when it comes to solving multi-
objective optimization problems [4]. For this reason, we are inter-
ested in using an EA to solve this problem. e problem includes
both discrete (which catheters) and continuous (dwell times) vari-
ables. Many state-of-the-art (multi-objective) EAs focus on either
discrete or continuous domains exclusively. Optimization where
discrete and continuous variables are present simultaneously is
explored relatively less and is referred to as mixed-integer optimiza-
tion. A recently introduced Genetic Algorithm for Model-Based
mixed-Integer opTimization (GAMBIT) has shown to be an eective
approach to single-objective optimization in the mixed-integer do-
main [12], especially in the case of black-box optimization, meaning
that no internal structure of the problem is assumed to be known
in advance. is makes GAMBIT exible and easily adaptable for
our multi-objective approach of BT pre-planning optimization.
Figure 1: Graphical representation of a patient’s anatomy
and implanted catheters.
2 BT TREATMENT PLANNING
2.1 Clinical practice
In BT for prostate cancer, the treatment targets are the prostate and
the seminal vesicles (see Fig. 1). e Organs At Risk (OARs), which
should be radiated as lile as possible, are the nearby organs, i.e.,
bladder, rectum, and urethra. Guided by live ultrasound images, a
typical High-Dose-Rate (HDR) prostate BT treatment starts with
implanting a number of catheters into the prostate through the
patient’s perineum skin (between scrotum and anus). e suitable
number of catheters and their proper positions depend on the size of
the prostate and its geometry in relation to other nearby organs (e.g.,
bladder and rectum). e inserted catheters need to be rmly xed
to prevent displacements. e patient is subsequently transferred to
the imaging room, where computed tomography (CT) or Magnetic
Resonance Imaging (MRI) scans of the pelvic cavity are acquired.
ese scans are then used to nalize the treatment plan.
First, the catheters, the targets, and OARs are delineated on the
CT/MRI scans in planning soware. e doctors then specify which
dwell positions in each catheter should be activated. For a given
dwell time of a source at a dwell position, more radiation dose
is delivered to nearby tissues than to faraway tissues. erefore,
to increase the probability of fully treating the target and sparing
healthy tissues at the same time, dwell positions inside the target
volumes are activated while the ones far away from the targets (e.g.,
at distances larger than 5mm) or too close to OARs are normally
not considered. A trivial treatment plan, in which dwell times take
on very large values, can kill all tumor cells but also causes necrosis
(i.e., non-physiological cell death) to healthy tissues. On the other
hand, another trivial treatment plan, where all dwell times are zero,
can eectively spare healthy tissues from radiation risks but such a
plan equals no treatment at all.
A specic seing of dwell times delivers a certain radiation
dose distribution to the tissues surrounding the catheters. e
dose distribution needs to be assessed by doctors to determine
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if such a seing can be clinically acceptable. A radiation dose
is prescribed for the entire prostate, termed the prescribed dose.
Tumor cells, which are more susceptible to radiation than healthy
cells, should receive at least the prescribed dose to be eectively
killed. Also, while healthy cells could recover from being radiated
at the prescribed dose level, they should not be radiated too much;
otherwise, healthy cells would be killed as well. However, it is
impossible to compute the exact amount of radiation received by
every cell since the number of cells is prohibitively numerous. Dose
distributions, therefore, are oen approximated by only computing
the radiation dose at a certain number of so-called dose calculation
points. Of key interest is how large the cumulative volume of an
organ covered by a certain dose is. Such information, termed Dose-
Volume-Histogram (DVH) indices, can be represented as V ox : the
volume (expressed either relatively or absolutely) of organ o that
received at least radiation dose level x . For example, international
GEC/ESTRO recommendations [7] state that treatment plans should
result in V prostate100 ≥ 95%, i.e., the prostate volume that receives at
least 100% of the prescribed dose should be ≥ 95% of the total
prostate volume. To prevent necrosis, it is required that V prostate200 ≤
20%, i.e., the prostate volume covered by 200% of the prescribed
dose should ≤ 20% of the total prostate volume. V prostate100 , therefore,
is a target coverage index while V prostate200 is an organ sparing index.
Similarly, there exist other sparing DVH indices for other OARs. For
example, it is recommended that V urethra110 ≤ 0.1cc , i.e., the urethra
volume covered by 110% of the prescribed dose should be ≤ 0.1cc .
Finally, because the vesicles may also contain tumor cells, there is
a constraint that V vesicles80 ≥ 95%. A full description of the current
clinical protocol in terms of DVH indices at the hospital involved
in this study is presented in Table 1.
Prostate Bladder Rectum Urethra Vesicles
V100 ≥ 95% V86 ≤ 1cc V78 ≤ 1cc V110 ≤ 0.1cc V80 ≥ 95%
V150 ≤ 50% V74 ≤ 2cc V74 ≤ 2cc
V200 ≤ 20%
Table 1: BT treatment planning in clinical practice at the
involved hospital: DVH index criteria.
e values of DVH indices in the clinical protocol are consulted
by the doctors when making treatment plans. Planning oen starts
with an initial plan proposed by BT treatment planning soware.
Note that it is dicult, however, to directly optimize DVH indices
due to their discrete nature. For example, maximizing the V prostate100
index equals maximizing the number of dose calculation points
inside the prostate that receives at least the prescribed dose. To
quickly achieve a result, planning soware therefore oen solves
simplied optimization models of the problem with local search
methods. It is thus not guaranteed that a treatment plan proposed
by available soware satises all DVH index criteria in the protocol
or that the plan is the best possible one for the patient case at
hand. Medical planners then need to manually adjust this proposed
plan. ey oen rst consider the DVH index that is violated the
most compared to the recommended protocol, and try to nd the
locations of violation, then change the dwell times of nearby dwell
positions to improve the index until satised. ey then continue
with a dierent DVH index that is now the most violated. Note that
improving a DVH index might deteriorate other indices, including
ones that have been previously worked on. e plan is adjusted in
such an iterative manner until the doctors are satised.
How good the DVH indices can be, depends on the quality of the
catheter implant and the geometry of the involved organs. Certain
implants will not allow all DVH indices to satisfy the recommended
protocol. For example, with too few or improperly placed catheters,
it is dicult to obtain V prostate100 ≥ 95% while meeting constraints on
indices of OARs. Similarly, if the rectum is too close to the prostate,
V rectum78 ≤ 1cc and V
prostate
100 ≥ 95% might not be achievable at the
same time. In such situations, for each specic case, the doctors
need to decide which indices are more important to be satised and
which indices can be compromised. Final approved treatment plans,
thus, might (slightly) violate some clinical protocol thresholds.
2.2 Multi-Objective Treatment Planning
BT treatment planning is intrinsically a multi-objective optimiza-
tion problem. e DVH indices in Table 1 can be categorized into
two groups: treatment target indices (i.e.,V prostate100 andV
vesicles
80 ) and or-
gan sparing indices. Candidate treatment plans that do not achieve
the minimum requirements on the indices in the clinical protocol
are less favorable than candidate plans that satisfy all protocol
thresholds. For a treatment target index, the larger its value is
(above the corresponding threshold), the beer it is. For an or-
gan sparing index, the lower its value is (below the corresponding
threshold), the beer it is. Optimizing treatment target indices re-
sults in increasing dwell times to make the target volumes covered
by the treatment dose level as large as possible, where the best value
is 100%. On the other hand, optimizing organ sparing indices results
in decreasing dwell times to make the organ volumes covered by
the radiation risk dose levels as small as possible, where the best
value is 0%/0cc . e two groups of DVH indices conict with each
other such that a utopian treatment plan yielding 100% for all target
coverage indices and 0%/0cc for all organ sparing indices does not
exist. Instead, the optimum of this multi-objective problem is a set
(i.e., Pareto-optimal set) of equally-good alternative plans which are
optimal in the sense that improving one objective deteriorates the
other objective, and vice versa.
ere are nine dierent DVH index criteria. We argue, however,
that the clinical protocol can be reformulated to a bi-objective
optimization problem without losing key insight into trade-os by
combining the DVH indices of the same group (i.e., target coverage
or organ sparing) into a representative objective of that group.
To this end, we employ a risk-averse perspective, meaning that a
treatment plan is evaluated to be only as good as the worst target
coverage index and theworst organ sparing index. More specically,
each candidate plan has two objective values: the Least Coverage
Index (LCI), which corresponds to the worst-scored DVH index in
the target coverage group, and the Least Safe Index (LSI), which
corresponds to the worst-scored DVH index value in the organ
sparing group. erefore, for a specic treatment plan, all indices
in a group are at least as good as the representative value of the
group. Such an approach has an analogy with the clinical practice
in the iterative focus on improving the current worst index at each
time as mentioned previously. Moreover, unlike the weighted-sum
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approach, where all criteria are added together, each DVH index in
our problem modeling is still, in eect, considered separately.
e feasible search space is enlarged to contain solutions that
violate the clinical protocol to some degree. ere are two reasons
for this. e rst is that, in this way, the clinically-feasible solu-
tions can be approached from both the clinically-feasible and the
clinically-infeasible space, making the search in these regions more
ecient. Secondly, we account for the fact that sometimes there
exists no treatment plan satisfying all clinical protocols (due to the
quality of the implants and/or the geometry of the involved organs,
see Section 2.1), and a treatment plan that (slightly) violates the
protocol must thus be accepted. To relax the clinical constraints,
the new upper bounds for organ sparing indices are increased four
times (e.g., V bladder86 ≤ 1cc in the protocol becomes V bladder86 ≤ 4cc
in the optimization model). e new lower bounds for target cov-
erage indices are also decreased accordingly as: V prostate100 ≥ 80%
and V vesicles80 ≥ 80%. e optimization constraints are presented
in Table 2. Let Vmaxx denote the clinical protocol threshold of
a dose level x for an organ. To measure and normalize the dis-
tance of an organ sparing index value to its corresponding upper
bound, we dene δ (Vx ) = 1 − Vx4×Vmaxx . e larger the value of δ
is, the beer the corresponding DVH index value Vx of that or-
gan is and how safe an organ is compared to the relaxed protocol
threshold, with a value of 0.75 meaning that the clinical protocol
constraint is met. e LSI objective value is dened as the minimum
δ value among all organ sparing indices. Similarly, the LCI objec-
tive value of a treatment plan is dened as the minimum coverage
value among all target coverage indices. For example, a treatment
plan with V prostate100 = 97%,V
vesicles
80 = 96%, V
prostate
150 = 19%,V
prostate
200 =
7%,V bladder86 = 0.5cc,V
bladder
74 = 1.3cc,V
rectum
78 = 0.4cc,V
rectum
74 = 1.2cc,
V urethra110 = 0.1cc would have the Least Coverage Index value as 0.96
(taking the value of V vesicles80 ) and the Least Safe Index value as 0.75
(corresponding with V urethra110 ).
Prostate Bladder Rectum Urethra Vesicles
V100 ≥ 80% V86 ≤ 4cc V78 ≤ 4cc V110 ≤ 0.4cc V80 ≥ 80%
V150 free V74 ≤ 8cc V74 ≤ 8cc
V200 ≤ 80%
f1 = min{V prostate100 ,V vesicles80 }
f2 = min{δ (V prostate150 ),δ (V
prostate
200 ),δ (V bladder86 ),δ (V bladder74 ),δ (V rectum78 ),
δ (V rectum74 ),δ (V urethra110 )}
f3 = number of catheters used.
Table 2: Multi-objective optimization model for BT treat-
ment planning. f1 and f2 should be maximized while f3
should be minimized. Because of the relaxation factor,
V
prostate
150 has become unconstrained.
In this paper, we focus on the pre-planning phase, i.e., before
the catheters are inserted. To generate data and problem input
that corresponds to real-world clinical practice, we are currently
bound to real-world clinical soware. Given a prostate BT patient, a
number of possible catheter congurations can be determined, aer
which the clinical soware provides information on these possible
catheter congurations and their corresponding dwell positions.
Hence, there is a restriction in the sense that the optimization can
only use pre-determined catheter positions. In the soware many
catheters can be placed, but in a real patient it is desirable to have
catheters not too close to each other to avoid complications. In
order to have both a large enough search space for interesting rst
results and a set of congurations in which catheters are not too
close to each other, we chose the set of possible congurations to
consist of 30 catheters for each patient.
e optimization problem now contains d discrete and c contin-
uous variables. e d discrete variables represent all the possible
catheter placement positions. Each of these variables takes on a bi-
nary value, where 1 represents placing the corresponding catheter,
and 0 not placing the catheter. Each of the continuous variables
represents the dwell time corresponding to a dwell position in a
catheter. Dwell times for dwell positions inside an inactive catheter
can be ignored.
3 MODEL-BASED MULTI-OBJECTIVE
MIXED-INTEGER EVOLUTIONARY
ALGORITHM
In this section we summarize key concepts and terminology pertain-
ing to mixed-integer and multi-objective optimization and provide
an overview and summary of GAMBIT, and introduce the Multi-
Objective GAMBIT (MO-GAMBIT).
3.1 Terminology
3.1.1 Mixed-integer optimization. A mixed-integer problem is
dened as follows:
max f (xd ,xc )
s.t. h(xd ,xc ) = 0, g(xd ,xc ) ≤ 0
Here, x represents the solution
x = xdxc = d0...dld−1 c0...clc−1
where di ∈ {0, 1}, ci ∈ R, and xd , xc are the groups of all dis-
crete and real-valued variables, respectively. ld and lc represent
the number of discrete and continuous variables. Moreover, f is
the objective function, and h and g are the sets of equality and
inequality constraint functions, respectively. If both sets are empty,
the mixed-integer problem is said to be unconstrained.
3.1.2 Multi-Objective Optimization. AMulti-Objective (MO) op-
timization problem consists ofm objectives fi (x), i ∈ {0, 1, . . . ,m−
1}, that without loss of generality, must all be maximized. e objec-
tive value vector of a solution x is f (x) = (f0(x), f1(x), .., fm−1(x)).
A solution x0 dominates a solution x1 (denoted x0  x1) if and
only if fi (x0) ≥ fi (x1),∀i ∈ {0, 1, . . . ,m − 1} and f (x0) , f (x1).
A solution x0 is Pareto optimal if and only if there does not exist
a solution x1 such that x1  x0. e Pareto-optimal set PS of
the problem at hand is the set of all Pareto-optimal solutions. e
Pareto-optimal front PF is the set of the objective value vectors of
all Pareto-optimal solutions. e goal of MO optimization is to nd
a set of non-dominated solutions whose objective value vectors
constitute a good approximation of the Pareto-optimal front [4].
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3.2 GAMBIT
GAMBIT is a recently introduced EA aimed at solvingmixed-integer
problems, especially in the black-box seing. Here, we give a brief
outline of GAMBIT. More details can be found in literature [12].
GAMBIT is a parameter-free model-based EA capable of learning
and exploiting dierent types of variable dependencies, through a
clustering mechanism and an integrated dependency-models mech-
anism. e ability to learn such dependencies (i.e., which groups
of variables have a joint synergistic eect on a solution’s quality)
allows for the creation of variable subsets which represent impor-
tant building blocks of the problem. ese building blocks can
be used to exploit problem structure and generate new and beer
solutions more eectively. Such exploitation of problem structure
based on dependencies is well-established for discrete and continu-
ous variables, respectively. Mixed-integer optimization introduces
new optimization challenges, however. e existence of discrete
and continuous variables creates a potential for intra- and inter-
variable dependencies that domain-specic model-based EAs are
not equipped to handle. GAMBIT therefore introduces a new way
to learn and process mixed inter-domain variable dependencies,
alongside intra-domain dependencies (i.e., in individual domains)
during optimization.
GAMBIT splits the population in each generation with the use
of a clustering algorithm as detailed in Figure 2. Each of the sub-
populations acquired is then subject to variation through the inte-
grated dependencymodels mechanism, summarized in pseudo-code
in Figure 3. Specically, a Family-Of-Subsets (FOS) model is learned
at the beginning of every generation, which is used to describe de-
pendencies and to create ospring solutions [13]. Essentially, a
FOS is a set of linkage sets. Each linkage set contains the indices of
the variables that are considered to be dependent. e linkage sets
may overlap. e FOS consists of three types of subsets: discrete,
continuous, and mixed. In its full black-box optimization congu-
ration discrete subsets are generated using a so-called linkage tree,
which is a specic type of FOS that was rst used in the algorithm
known as Linkage Tree Genetic Algorithm (LTGA), which is now
considered to be an instance of the Gene-pool Optimal Mixing Evo-
lutionary Algorithm (GOMEA) family [13]. e linkage tree is a
FOS structure acquired by building from the boom up (i.e., start-
ing with singleton subsets of problem variables) a tree of subsets
by means of a hierarchical clustering algorithm based on mutual
information between pairs of variables. e linkage tree has 2ld − 1
discrete subsets representing important building blocks in the dis-
crete domain. e same number of continuous subsets are added
to the FOS, each containing every continuous problem variable.
Additionally, lc + ld mixed subsets are added to the FOS by building
another linkage tree constrained to merge discrete and continuous
variables using a mixed mutual information metric, described in
detail in [12]. Such mixed subsets allow for the consideration of dis-
crete and continuous variables together, resulting in the ability to
exploit potential mixed variable dependencies. Each type of subset
is processed with a corresponding mechanism type to generate new
solutions. Once all subsets are processed, new solutions replace the
previous population and the clustering process begins anew.
GAMBIT Overview
P ← GenerateAndEvalRandomPopulation(n)
while ¬TerminationCriterionSatisfied do
C ← DetermineClusterCenters(P,k)
for j ∈ {0, 1, . . . ,k − 1} do
Pk ← GrowSubPopFromCenters(P,Ck )
O′k ← IntegratedModelsMechanism(Pk )P ← O′0 ∪ O′1... ∪ O′k−1
Figure 2: Pseudo-code overview of GAMBIT. P represents
the population of size n. C contains k cluster (also called sub-
population) centers. Pi represents the i-th sub-population
and O′i is the ospring generated from sub-population Pi .
Integrated Model Mechanism for a sub-population Pk
IntegratedModelMechanism(Pk )
F = LearnFOS(Pk )
for i ∈ {0, 1, . . . , (|F | − 1)} do
if F i is all continuous then
S ← TruncationSelection(Pk ,τ )
UpdateContinuousModel(k,S)
for j ∈ {0, 1, . . . ,n − 1} do
((Pk )j )F i ← SampleContinuousModel(k, F i )
EvaluateFitness((Pk )j )
if F i is all discrete then
for j ∈ {0, 1, . . . ,n − 1} do
O ← (Pk )j
donor ← GetRandomSolution(Pk )
(O)F i ← (donor )F i
EvaluateFitness(O)
if tness(O) at least as good as tness((Pk )j ) then
((Pk )j )F i ← (O)F i
if F i is mixed then
Pksub [0, ...,k − 1] ← GroupIntoClusters(i,k,Pk )
UpdateMixedSubModels(i,Pksub )
for j ∈ {0, 1, . . . ,n − 1} do
SubID ← DetermineSubPopulation(j)
O ← (Pk )j
(O)F i ← SampleSubModel(i,Pksub [SubID])
EvaluateFitness(O)
if tness(O) at least as good as tness((Pk )j ) then
((Pk )j )F i ← (Ok )F i
return Pk
Figure 3: Pseudo-code for generating solutions with GAM-
BITs Integrated Models Mechanism.
3.3 Multi-Objective GAMBIT
In this paper we introduce MO-GAMBIT that brings the black-
box mixed-integer optimization capabilities of GAMBIT into the
MO domain. e approach to handle MO problem landscapes with
GAMBIT is to include mechanisms designated specically to exploit
the multi-objective nature of the problem landscape, such as an
elitist archive and the ability to rank solutions in a multi-objective
space. In this section, we outline the key components used in the
design ofMO-GAMBIT and its specic application to brachytherapy
pre-treatment planning.
3.3.1 Elitist Archive. In previous work on multi-objective EAs,
elitism has been shown to be very important [3]. For this reason,
an elitist archive is added in MO-GAMBIT. Because real-valued
variables are involved, we use a technique that adaptively changes
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the grid that governs the elitist archive so as to harbor a predened
maximum number of solutions, preventing occurrences of very
similar solutions in the archive while promoting diversity. For
more details, see [10].
3.3.2 Selection and Variation. e selection and variation mech-
anisms are changed in MO-GAMBIT to account for the MO nature
of the problems, and to make use of the elitist archive. Solutions
are still clustered at every generation, however clustering is per-
formed in the objective space. is allows MO-GAMBIT to special-
ize model-based optimization in dierent areas of the Pareto front.
Variation proceeds by improving existing solutions, as is reminis-
cent of GOMEA, in case of discrete and mixed linkage sets. Solution
parts are copied from donors and mixed into solutions, and changes
are only accepted in case of a multi-objective improvement. Con-
tinuous variables are supplied from normal distributions estimated
from a population-based MO rank-based selection [3] following
procedures of the real-valued EDA known as iAMaLGaM [2] and
its multi-objective counterpart iMAMaLGaM [1]. For an overview
in pseudo-code, see Figure 3.
Upon sampling new solutions, the clusters are populated with
solutions from the previous generation as well as a fraction of
τ = 0.35 elitist archive solutions that are closest to the given cluster
in the objective space, using a Euclidean distance metric. If not
enough elitist archive solutions exist, the entire archive is used
for each cluster. is combination of solutions from the previous
generation and the elitist archive is used to estimate and sample new
solutions. Previously, in MO versions of GOMEA and iAMaLGaM
this was found to have a positive eect on convergence to high-
quality solutions [1, 10].
3.3.3 Population and Cluster Sizing. Determining parameters
such as the population size or number of clusters can be crucial
for the eectiveness of EAs. Small population sizes or insucient
number of clusters can lead to premature convergence. Conversely,
too many clusters or too large population sizes can result in a
very large overhead. To avoid the need to specify these parame-
ters, MO-GAMBIT adapts a interleaved multistart scheme, which
dynamically introduces larger population sizes. Specically, the
scheme runs dierently sized instances of GAMBIT in an inter-
leaved fashion. For every γ = 2 generations of a certain instance
of GAMBIT, one generation of an instance of GAMBIT with twice
the population size and one more cluster is performed. By doing
so, smaller population sizes perform more generational steps than
larger ones. e scheme already used with GAMBIT is altered to
make use of the elitist archive. With GAMBIT, all the dierently
sized instances are completely independent of each other. In MO-
GAMBIT the elitist archive is shared over all instances, allowing to
transfer knowledge about high-quality solutions already obtained
with the smaller populations.
3.3.4 Problem-Specific Knowledge. A strictly black-box opti-
mization algorithm may be a great starting point when considering
new problems. In a real-world seing however, some problem-
specic information can potentially improve performance. In our
case consider that every discrete variable d0,d1, ...,dld−1 is associ-
ated with an independent set of dwell positions. Instead of learning
mixed-variable dependencies, which could result in a signicant
overhead, a pre-dened mixed-variable subset structure is dened
that captures key dependencies. Specically, each subset contains
one discrete variable (representing the catheter) and the set of con-
tinuous variables that represent the dwell positions associated with
this catheter. Moreover, because we do not expect strong depen-
dencies to exist between continuous variables, we do not model
them jointly in one linkage set as per default in GAMBIT, but rather
model them independently, i.e., univariately to reduce substantially
the overhead of sampling high-dimensional Gaussian distributions.
3.3.5 Sliced 3-objective optimization. We minimize the num-
ber of catheters in one of the objectives. However, we slice this
3-dimensional problem into many 2-dimensional multi-objective
problems. Lile relation between congurationswith dierent num-
bers of catheters exists, and switching a catheter on (i.e., changing
a binary variable from 0 to 1) has huge impact, implying there
exist big jumps in the search space across dierent numbers of
catheters, making a direct 3-objective optimization approach ex-
tra dicult. A sliced approach allows an instance of GAMBIT to
focus on congurations with the same number of catheters, while
at the same time making it easier to parallelize the optimization
across congurations with dierent number of catheters. We refer
to our approach as a multi-layer approach, where in a given layer
only combinations with the of number of catheters are allowed.
Because solutions resulting in a dierent numbers of catheters can
be created in variation, a simple random repair mechanism is used
to activate or deactivate a required number of catheters.
4 EXPERIMENTS
4.1 Setup
Clinical data from three recently treated patients is used for opti-
mization. For each patient, there are 30 possible catheter locations,
resulting in 30 MO-GAMBIT instances, each performing optimiza-
tion on a 2-objective mixed-integer problem. e duration of opti-
mization for each MO-GAMBIT instance is limited to 48 hours (on
an AMD Opteron(tm) Processor 6386 SE and Intel(R) Xeon(R) CPU
E5 2699 v4), with all 30 congurations executed in parallel. During
the optimization 20,000 randomly chosen dose calculation points
are used to compute the objective values for every function eval-
uation. To ensure sucient accuracy in reporting nal outcomes,
the nal set of solutions on the Pareto front is re-evaluated with
100,000 dose calculation points, which is commonly considered to
be suciently accurate.
4.2 Results
Results in Figure 4 illustrate the quality of solutions which can be
acquired with dierent numbers of catheters. e results provide a
clear illustration of the trade-os between the objectives. A solution
that satises clinical protocol lies in the area of the Pareto front
where LCI ≥ 0.95 while LSI ≥ 0.75. e clinically approved solutions
for the considered patients all used 16 catheters. Figure 4 shows
that it is possible to obtain approvable, high-quality plans using
smaller numbers of catheters. Very lile quality of solutions is lost
when using a few less catheters. Only when many less catheters
are used (less than 9 for the tested patients) the resulting solutions
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Figure 4: Pareto fronts obtained with MO-GAMBIT illustrating trade-os between three objectives for three patients. e
color coding represents the number of catheters. Green points represent the high-quality solutions selected for visualization
in Figure 5 with 10,12 and 16 catheters for patients 1,2 and 3 respectively.
lead to clearly inferior and unacceptable plans when considering
the other two objectives.
Outcomes still dier widely between patients. More solutions
with beer objective values are found for patient 2. Increasing
the number of catheters for patient 2 provides bigger benets in
terms of the LCI and LSI objectives than for patient 1. is suggests
that plan optimization can substantially dier for dierent patients,
further highlighting the potential benets of enabling insight into
possible trade-os and especially the added value of considering
the number of catheters as part of optimization.
When the number of catheters is small, the addition of catheters
can substantially improve the trade-os between target coverage
and organ sparing (e.g., see the gap between the 2D Pareto fronts
of using less vs more than 5 catheters). However, when the number
of catheters is sucient, the trade-o improvement due to adding
more catheters clearly diminishes. It would be interesting for fu-
ture work to investigate the marginal added value of each catheter
insertion with respect to the (2D) Pareto-front improvement when
considering a larger patient group.
e severity of trade-os between the LCI and LSI is much higher
in the more extreme regions of the Pareto front. For example, at the
area where LCI is larger than 0.95, trying to increase target coverage
can quickly worsen the sparing of OARs. On the other hand, if a
treatment plan of LCI = 0.95 is satisable, the healthy tissues can
be considerably spared from radiation risks (e.g., compare the high
value of LSI of solutions having LCI = 0.95). is is very likely part
of the notorious practical hardness of deciding upon what values
for a good plan to ultimately use.
Figure 5 illustrates selected plans obtained with MO-GAMBIT
with only 10, 12 and 16 catheters for patients 1, 2 and 3 respectively.
All DVH indices satisfy the clinical constraints. For these plans
a doctor can decide whether it is acceptable, or whether a factor
should be improved at the expense of another factor. For example,
it may be desirable to use less than 12 catheters for patient 2, even
withworse target coverage (but still satisfying all constraints). From
the complete set of Pareto optimal solutions, a candidate plan in
that trade-o direction can be taken, for which the same decision
can be made, until nally the best Pareto-optimal solution is chosen
without optimization needing to be re-ran.
5 DISCUSSION AND CONCLUSIONS
is paper considers BT treatment pre-planning optimization from
a multi-objective perspective, while combining, for the rst time,
a true multi-objective optimization approach with optimization
directly on clinical evaluation criteria and considering trade-os
between key objectives: the covering of targets, the sparing of
organs at risk, and the number of catheters. In current medical
practice devising such plans depends heavily on the expertise of
doctors. We wish to assist them by enabling the ability to view and
consider a set of approximated Pareto optimal solutionswith respect
to the aforementioned objectives. With this ability, doctors may
gain additional insight into possible treatment plans, potentially
resulting in improved patient care. As a rst proof of concept to
this end, we combined real-world clinical soware with a novel
extension of GAMBIT to multi-objective optimization.
e generated three-objective Pareto fronts for real-world pa-
tients provided a useful overview of possible treatment plans with
respect to the number of catheters used, potential risk to healthy
organs, and the coverage of the targets. Including, for the rst
time, the number and location of possible catheters placements
with a multi-objective optimization approach allowed us to gain
new, clinically relevant insight into BT pre-planning optimization.
We were able to obtain sets of clinically acceptable non-dominated
solutions, and indicated that it appears possible to obtain good
solutions with smaller numbers of catheters compared to the clini-
cally used plans for the tested patients. Using a larger number of
catheters can lead to beer, clinically acceptable solutions in terms
of the other objectives, but the added value in key DVH indices
used to evaluate plans strongly diminishes when using more than
around 10 catheters. Outcomes further present insights into trade-
os between other key objectives, allowing doctors to utilize their
expertise, and consider which of such trade-os may be benecial
to the patient without re-running optimization.
Our approach based on MO-GAMBIT provides a new, promising
and insightful approach for optimization of BT treatment plans,
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but further improvements to this approach are needed and pos-
sible. Optimization mechanisms which consider problem struc-
ture specics such as evaluation decomposability could potentially
improve optimization speed substantially. Combined with other
problem-specic mechanisms, such as a multi-resolution approach
to increasing the accuracy of dose calculations over time, a many-
fold speedup may be obtained, reducing required run times to
minutes rather than hours (even though in the pre-planning phase
this is far less of an issue than when making treatment plans aer
physical catheter placement has taken place) and allowing for more
exhaustive exploration of the search space, potentially leading to
discovery of even more high-quality non-dominated solutions.
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(a) Selected patient 1 solution
Prostate Vesicles
V100 = 96.39% V80 = 96.40%
Prostate Bladder Rectum Urethra
V150 = 27.20% V86 = 0.58cc V78 = 0.78cc V110 = 0.09cc
V200 = 11.05% V74 = 1.78cc V74 = 1.09cc
(b) Selected patient 2 solution
Prostate Vesicles
V100 = 98.53% V80 = 99.00%
Prostate Bladder Rectum Urethra
V150 = 19.72% V86 = 0.52cc V78 = 0.81cc V110 = 0.08cc
V200 = 6.76% V74 = 1.82cc V74 = 1.21cc
(c) Selected patient 3 solution
Prostate Vesicles
V100 = 95.29% V80 = 95.50%
Prostate Bladder Rectum Urethra
V150 = 27.24% V86 = 0.85cc V78 = 0.50cc V110 = 0.09cc
V200 = 8.35% V74 = 1.87cc V74 = 0.69cc
Figure 5: Selected solutions from the Pareto fronts of pa-
tients 1, 2 and 3 resulting in a high-quality plan with 10, 12
and 16 catheters, respectively. e gures on the right show
the corresponding isodose lines in selected slices on the cor-
responding MRI scans, where red dots are active dwell posi-
tions. e tables show the corresponding DVH indices. All
DVH index values satisfy the clinical constraints.
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